Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 625.49
TGTX's Cash-to-Debt is ranked higher than
56% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. TGTX: 625.49 )
Ranked among companies with meaningful Cash-to-Debt only.
TGTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: No Debt Max: No Debt
Current: 625.49
Equity-to-Asset 0.82
TGTX's Equity-to-Asset is ranked higher than
50% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. TGTX: 0.82 )
Ranked among companies with meaningful Equity-to-Asset only.
TGTX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.16  Med: 0.87 Max: 0.97
Current: 0.82
0.16
0.97
Piotroski F-Score: 3
Altman Z-Score: 17.24
Beneish M-Score: -4.91
WACC vs ROIC
18.57%
-1342.33%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -60948.68
TGTX's Operating Margin % is ranked lower than
99% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. TGTX: -60948.68 )
Ranked among companies with meaningful Operating Margin % only.
TGTX' s Operating Margin % Range Over the Past 10 Years
Min: -141552.63  Med: -41565.79 Max: -15109.21
Current: -60948.68
-141552.63
-15109.21
Net Margin % -60613.16
TGTX's Net Margin % is ranked lower than
98% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. TGTX: -60613.16 )
Ranked among companies with meaningful Net Margin % only.
TGTX' s Net Margin % Range Over the Past 10 Years
Min: -95121.05  Med: -41413.82 Max: -13472.37
Current: -60613.16
-95121.05
-13472.37
ROE % -127.32
TGTX's ROE % is ranked lower than
81% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. TGTX: -127.32 )
Ranked among companies with meaningful ROE % only.
TGTX' s ROE % Range Over the Past 10 Years
Min: -3919.22  Med: -92.85 Max: -40.04
Current: -127.32
-3919.22
-40.04
ROA % -102.69
TGTX's ROA % is ranked lower than
83% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. TGTX: -102.69 )
Ranked among companies with meaningful ROA % only.
TGTX' s ROA % Range Over the Past 10 Years
Min: -543.33  Med: -87.87 Max: 6.57
Current: -102.69
-543.33
6.57
ROC (Joel Greenblatt) % -7726.58
TGTX's ROC (Joel Greenblatt) % is ranked lower than
84% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. TGTX: -7726.58 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TGTX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -58800  Med: -17586.18 Max: -6883.38
Current: -7726.58
-58800
-6883.38
3-Year Revenue Growth Rate -20.60
TGTX's 3-Year Revenue Growth Rate is ranked lower than
75% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. TGTX: -20.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TGTX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 44.2
Current: -20.6
0
44.2
3-Year EBITDA Growth Rate 28.00
TGTX's 3-Year EBITDA Growth Rate is ranked higher than
79% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. TGTX: 28.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TGTX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -51.05 Max: 73
Current: 28
0
73
3-Year EPS without NRI Growth Rate 25.50
TGTX's 3-Year EPS without NRI Growth Rate is ranked higher than
78% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. TGTX: 25.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TGTX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -42.75 Max: 76.5
Current: 25.5
0
76.5
GuruFocus has detected 4 Warning Signs with TG Therapeutics Inc $TGTX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TGTX's 30-Y Financials

Financials (Next Earnings Date: 2017-08-05 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

TGTX Guru Trades in

Q2 2015

TGTX Guru Trades in Q2 2015

Jim Simons Sold Out
» More
Q2 2016

TGTX Guru Trades in Q2 2016

Paul Tudor Jones 23,516 sh (New)
» More
Q3 2016

TGTX Guru Trades in Q3 2016

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with TGTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:AMRI, NYSE:MYOV, NAS:AMRN, NAS:ALDR, NYSE:BHVN, NAS:ASND, NAS:AKAO, NAS:ZIOP, NAS:FPRX, NAS:IMMU, NAS:AIMT, NAS:ESPR, NAS:CLLS, OTCPK:IPHYF, NAS:BYSI, NAS:ADRO, NAS:KERX, NAS:EPZM, NAS:FWP, NAS:OMER » details
Traded in other countries:NKB2.Germany,
Headquarter Location:USA
TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development & commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

TG Therapeutics Inc, was incorporated in Delaware in 1993. The Company is a biopharmaceutical company focused on the acquisition, development, and commercialization of new and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the Company is developing two therapies targeting hematological malignancies. TGTX-1101 or ublituximab which is a novel, third generation monoclonal antibody that targets a specific and single epitope on the CD20 antigen found on mature B-lymphocytes, currently in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. The Company is also developing TGR-1202, an orally available PI3K delta inhibitor. The phosphoinositide-3-kinases or PI3Ks are a family of enzymes involved in cellular functions, including cell proliferation and survival, cell differentiation, intracellular trafficking and immunity. There are four isoforms of PI3K: alpha, beta, delta, and gamma, of which the delta isoform is strongly expressed in cells of hematopoietic origin, and often implicated in B-cell related lymphomas. TGR-1202 is being developed jointly with Rhizen Pharmaceuticals, S A. TGR-1202 has demonstrated activity in preclinical xenograft models and primary cells from patients for hematologic cancers. The Company competes with Roche Group, Gazyva, Spectrum Pharmaceutical, Dr. Reddy's Laboratories', among others.

Top Ranked Articles about TG Therapeutics Inc

TG Therapeutics, Inc. Announces Successful Outcome from Pre-Planned Interim Analysis by Independent DSMB in the UNITY-CLL Phase 3 Trial
TG Therapeutics, Inc. Provides Business Update and Reports First Quarter 2017 Financial Results
TG Therapeutics, Inc. to Host Conference Call on First Quarter 2017 Financial Results and Business Update
TG Therapeutics Announces Preliminary Results from Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the American Academy of Neurology 69th Annual Meeting
TG Therapeutics, Inc. Recaps Schedule of Data Presentation at the Upcoming American Academy of Neurology 69th Annual Meeting
TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology
TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Company’s Anti-PD-L1 Monoclonal Antibody at the American Association for Cancer Research Annual Meeting
TG Therapeutics, Inc. Announces Preclinical Data Presentation at the 2017 American Association for Cancer Research (AACR) Annual Meeting

NEW YORK, March 20, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that preclinical data for the Company’s anti-PD-L1 monoclonal antibody, has been selected for presentation at the upcoming American Association for Cancer Research (AACR) annual meeting, to be held April 1-5, 2017, at the Walter E. Washington Convention Center in Washington, D.C.
The presentation details are as follows: • Title: Preclinical characterization of a novel fully human IgG1 anti-PD-L1 mAb CK-301  Abstract Number: 4606
Date and Time: Tuesday, April 4, 2017, 1:00 PM - 5:00 PM ET
Session: Immunoconjugates and Antibodies
Location: Halls A-C, Poster Section 26
Poster Number: 21
A copy of the above referenced abstract can be viewed online through the AACR meeting website at www.aacr.org. Following the presentation, the data presented will be available on the Publications page of the Company’s website at www.tgtherapeutics.com.
ABOUT TG THERAPEUTICS, INC. TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 also in clinical development for autoimmune disorders. The Company also has preclinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City. Cautionary Statement Some of the statements included in this press release, particularly those anticipating future clinical trials, timing of clinical trials for anti-PD-L1 antibodies and business prospects and potential uses for anti-PD-L1 antibodies may be forward-looking statements that involve a number of risks and uncertainties.  For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to identify anti-PD-L1 antibodies suitable for clinical development, our ability to successfully and cost-effectively complete preclinical and clinical trials for anti-PD-L1 antibodies; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the data analyses from prior preclinical and clinical trials; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission.  Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only. TGTX - G
CONTACT:
Jenna Bosco
Vice President, Investor Relations
TG Therapeutics, Inc.
Telephone: 212.554.4351
Email: [email protected]

Read more...
TG Therapeutics, Inc. to Present at the 27th Annual Oppenheimer Healthcare Conference

Presentation Scheduled for Tuesday, March 21, 2017 at 3:20pm ET
NEW YORK, March 17, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present at the 27th Annual Oppenheimer Healthcare Conference, being held at The Westin Grand Central Hotel in New York City. The presentation is scheduled to take place on Tuesday, March 21, 2017 at 3:20pm ET. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at www.tgtherapeutics.com.ABOUT TG THERAPEUTICS, INC.TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 recently entering clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.TGTX - G
CONTACT:
Jenna Bosco
Vice President- Investor Relations
TG Therapeutics, Inc.
Telephone: 212.554.4351
Email: [email protected]

Read more...
TG Therapeutics, Inc. to Present at the 29th Annual ROTH Conference

Presentation Scheduled for Tuesday, March 14, 2017 at 3:00pm PT

NEW YORK, March 13, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present at the 29th Annual ROTH Conference, being held at the Ritz Carlton in Laguna Niguel, California. The presentation is scheduled to take place on Tuesday, March 14, 2017 at 3:00pm PT. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at www.tgtherapeutics.com.
ABOUT TG THERAPEUTICS, INC. TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 recently entering clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City. TGTX - G
CONTACT:
Jenna Bosco
Vice President- Investor Relations
TG Therapeutics, Inc.
Telephone: 212.554.4351
Email: [email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 6.89
TGTX's PB Ratio is ranked lower than
93% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. TGTX: 6.89 )
Ranked among companies with meaningful PB Ratio only.
TGTX' s PB Ratio Range Over the Past 10 Years
Min: 2.51  Med: 6.23 Max: 17.69
Current: 6.89
2.51
17.69
PS Ratio 3012.50
TGTX's PS Ratio is ranked lower than
99% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. TGTX: 3012.50 )
Ranked among companies with meaningful PS Ratio only.
TGTX' s PS Ratio Range Over the Past 10 Years
Min: 558.33  Med: 2090 Max: 4670
Current: 3012.5
558.33
4670
Current Ratio 6.03
TGTX's Current Ratio is ranked lower than
62% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. TGTX: 6.03 )
Ranked among companies with meaningful Current Ratio only.
TGTX' s Current Ratio Range Over the Past 10 Years
Min: 0.06  Med: 4.56 Max: 35.5
Current: 6.03
0.06
35.5
Quick Ratio 6.03
TGTX's Quick Ratio is ranked lower than
58% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. TGTX: 6.03 )
Ranked among companies with meaningful Quick Ratio only.
TGTX' s Quick Ratio Range Over the Past 10 Years
Min: 0.06  Med: 4.56 Max: 35.5
Current: 6.03
0.06
35.5
Days Sales Outstanding 55.23
TGTX's Days Sales Outstanding is ranked lower than
90% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. TGTX: 55.23 )
Ranked among companies with meaningful Days Sales Outstanding only.
TGTX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 64.84  Med: 204.11 Max: 446.64
Current: 55.23
64.84
446.64

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -18.30
TGTX's 3-Year Average Share Buyback Ratio is ranked lower than
66% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. TGTX: -18.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TGTX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -851.2  Med: -22.15 Max: 0
Current: -18.3
-851.2
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 7.99
TGTX's Price-to-Net-Cash is ranked lower than
84% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. TGTX: 7.99 )
Ranked among companies with meaningful Price-to-Net-Cash only.
TGTX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.19  Med: 9.18 Max: 620.4
Current: 7.99
1.19
620.4
Price-to-Net-Current-Asset-Value 7.17
TGTX's Price-to-Net-Current-Asset-Value is ranked lower than
85% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. TGTX: 7.17 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
TGTX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.18  Med: 7.8 Max: 3515.58
Current: 7.17
1.18
3515.58
Price-to-Tangible-Book 6.94
TGTX's Price-to-Tangible-Book is ranked lower than
89% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. TGTX: 6.94 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
TGTX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.65  Med: 7.22 Max: 5631.96
Current: 6.94
0.65
5631.96
Price-to-Median-PS-Value 1.44
TGTX's Price-to-Median-PS-Value is ranked lower than
74% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. TGTX: 1.44 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TGTX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.31  Med: 1.07 Max: 1.98
Current: 1.44
0.31
1.98
Earnings Yield (Greenblatt) % -13.39
TGTX's Earnings Yield (Greenblatt) % is ranked lower than
62% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. TGTX: -13.39 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TGTX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -3772.5  Med: 194.4 Max: 1470.1
Current: -13.39
-3772.5
1470.1

More Statistics

Revenue (TTM) (Mil) $0.15
EPS (TTM) $ -1.84
Beta2.70
Short Percentage of Float29.28%
52-Week Range $4.10 - 15.05
Shares Outstanding (Mil)66.78

Analyst Estimate

Dec18 Dec19
Revenue (Mil $) 0 7
EPS ($) -1.61 -1.86
EPS without NRI ($) -1.61 -1.86
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for TGTX

Headlines

Articles On GuruFocus.com
TG Therapeutics, Inc. Announces Successful Outcome from Pre-Planned Interim Analysis by Independent May 23 2017 
TG Therapeutics, Inc. Provides Business Update and Reports First Quarter 2017 Financial Results May 05 2017 
TG Therapeutics, Inc. to Host Conference Call on First Quarter 2017 Financial Results and Business U May 03 2017 
TG Therapeutics Announces Preliminary Results from Ongoing Phase 2 Study of TG-1101 (ublituximab) in Apr 28 2017 
TG Therapeutics, Inc. Recaps Schedule of Data Presentation at the Upcoming American Academy of Neuro Apr 24 2017 
TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 53rd Annual Meeting of t Apr 20 2017 
TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Company’s Anti-PD-L1 Monoc Apr 04 2017 
TG Therapeutics, Inc. Announces Preclinical Data Presentation at the 2017 American Association for C Mar 20 2017 
TG Therapeutics, Inc. to Present at the 27th Annual Oppenheimer Healthcare Conference Mar 17 2017 
TG Therapeutics, Inc. to Present at the 29th Annual ROTH Conference Mar 13 2017 

More From Other Websites
5 Stocks Setting Up for Big Breakouts May 26 2017
TG Therapeutics Stock Climbs After Successfully Completed Analysis in UNITY-CLL May 23 2017
TG Therapeutics, Inc. Announces Successful Outcome from Pre-Planned Interim Analysis by Independent... May 23 2017
TG Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : TGTX-US : May 22,... May 22 2017
TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 14th International... May 19 2017
TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 22nd European Hematology... May 18 2017
TG Therapeutics, Inc. Recaps Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the... May 17 2017
ETFs with exposure to TG Therapeutics, Inc. : May 15, 2017 May 15 2017
TG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 May 12 2017
TG Therapeutics, Inc. – Value Analysis (NASDAQ:TGTX) : May 11, 2017 May 11 2017
3 Intriguing Cancer Drugs With Data Coming at ASCO Next Month May 05 2017
TG Therapeutics reports 1Q loss May 05 2017
TG Therapeutics, Inc. Provides Business Update and Reports First Quarter 2017 Financial Results May 05 2017
TG Therapeutics, Inc. to Host Conference Call on First Quarter 2017 Financial Results and Business... May 03 2017
3 Best Biotech Stocks During Trump's First 100 Days May 01 2017
TG Therapeutics Announces Preliminary Results from Ongoing Phase 2 Study of TG-1101 (ublituximab) in... Apr 28 2017
ETFs with exposure to TG Therapeutics, Inc. : April 26, 2017 Apr 26 2017
Harry Boxer’s two infrastructure stocks to watch Apr 26 2017
Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and TG Therapeutics Apr 26 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)